Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shinya Toyokuni. (2011) Iron as a target of chemoprevention for longevity in humans. Free Radical Research 45:8, pages 906-917.
Read now
Read now
Amber Fullmer, Hagop Kantarjian, Jorge Cortes & Elias Jabbour. (2011) New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leukemia & Lymphoma 52:sup1, pages 81-91.
Read now
Read now
Articles from other publishers (13)
Željko Antić, Jana Lentes & Anke K. Bergmann. (2023) Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia. Best Practice & Research Clinical Haematology 36:4, pages 101511.
Crossref
Crossref
Min Chen, Lulu Liu, Lingli Zhang, Yunzhu Lin, Xiaoxi Lu, Hao Yang & Jiaqi Ni. (2023) Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China. BMC Health Services Research 23:1.
Crossref
Crossref
Philippe Chouvarine, Željko Antić, Jana Lentes, Charlotte Schröder, Julia Alten, Monika Brüggemann, Enrique Carrillo-de Santa Pau, Thomas Illig, Teresa Laguna, Denis Schewe, Martin Stanulla, Ming Tang, Martin Zimmermann, Martin Schrappe, Brigitte Schlegelberger, Gunnar Cario & Anke K. Bergmann. (2021) Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics. Cancers 13:22, pages 5653.
Crossref
Crossref
Nicolas Batty, Joseph Shatzel, Samuel Wiles, Mathew Kabalan, Rohit Sharma, Jonathan Pang, David Yi, Iris Alatovic, Sana Saif, Deepika Narasimha, Joseph LaPenna, Anthony Troitino, Kristopher Attwood, Michael Weinstein, Eric Murawski, Mathew Valerio, Yong Yin & Meir Wetzler. (2014) Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. Journal of Cancer Policy 2:2, pages 40-44.
Crossref
Crossref
Tariq I. Mughal, Jerald P. Radich, Richard A. Van Etten, Alfonso Quintás‐Cardama, Tomasz Skorski, Farhad Ravandi, Daniel J. DeAngelo, Carlo Gambacorti‐Passerini, Giovanni Martinelli & Ayalew Tefferi. (2011) Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop. American Journal of Hematology 86:9, pages 811-819.
Crossref
Crossref
Tri Nguyen, Yun Dai, Elisa Attkisson, Lora Kramer, Nicholas Jordan, Nguyen Nguyen, Nikhil Kolluri, Markus Muschen & Steven Grant. (2011)
HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells
In Vitro
and
In Vivo
. Clinical Cancer Research 17:10, pages 3219-3232.
Crossref
Crossref
Andrés F. Buitrago, Luis E. Silva, Leidy P. Prada & Libardo Lobato. (2011) Derrame pericárdico con inminente taponamiento cardiaco secundario a inhibidor de la tirosina quinasa. Reporte de un caso. Revista Colombiana de Cardiología 18:2, pages 119-123.
Crossref
Crossref
Zhuang Zuo, Dan Jones, Hui Yao, Deborah A Thomas, Susan O'Brien, Farhad Ravandi, Hagop M Kantarjian, Lynne V Abruzzo, L Jeffrey Medeiros, Su S Chen & Rajyalakshmi Luthra. (2010) A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Modern Pathology 23:11, pages 1524-1534.
Crossref
Crossref
Shun’ichiro Taniguchi, Minoru Fujimori, Takayuki Sasaki, Hiroko Tsutsui, Yuko Shimatani, Keiichi Seki & Jun Amano. (2010) Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Science 101:9, pages 1925-1932.
Crossref
Crossref
Amber Fullmer, Jorge Cortes, Hagop Kantarjian & Elias Jabbour. (2010) ASH 2009 meeting report—Top 10 clinically oriented abstracts in acute leukemia. American Journal of Hematology 85:4, pages 277-280.
Crossref
Crossref
Amber Fullmer & Elias Jabbour. (2010) Treatment of Philadelphia‐positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?. American Journal of Hematology 85:3, pages 158-159.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref
Camillo Porta & Federica Tagliani. (2008) The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia. Oncology Reviews 2:2, pages 67-68.
Crossref
Crossref